Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
The information provided is for general purposes only and should not be construed or used as individual exercise advice
Consult your healthcare provider for more information and medical advice about Ozempic or compounded semaglutide
Call your doctor for medical advice about side effects, or report them to the FDA at 1-800-FDA-1088
The resolution, which was unanimously approved by the City Council, would bring together public health experts, doctors, patients, insurers, and economists to evaluate the clinical and economic impacts of these medications and chart a thoughtful, evidence-based path forward
It is prevalent in the wild throughout much of North America and Eurasia